Moreover, a previous study demonstrated that individuals with metastatic melanoma treated with a combination of anti-CTLA-4 and anti-PD-1 therapies exhibited activation of the β-catenin signaling pathway and deletion of the PTEN gene, two oncogenic abnormalities associated with insufficient T-cell infiltration into tumor sites. This evidence concerns the gene PDCD1 and metastatic melanoma.